Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > 01302 LIFETECH SCI > Detailed Quotes

01302 LIFETECH SCI

Watchlist
2.480
+0.030+1.22%
Closed 08/12 16:08 CCT
High
2.480
Open
2.460
Turnover
3.96M
Low
2.410
Pre Close
2.450
Volume
1.62M
Market Cap
11.48B
P/E(TTM)
32.21
52wk High
4.500
Shares
4.63B
P/E(Static)
32.21
52wk Low
2.010
Float Cap
11.48B
Bid/Ask %
-12.64%
Historical High
5.980
Shs Float
4.63B
Volume Ratio
0.73
Historical Low
0.190
Dividend TTM
--
Div Yield TTM
--
P/B
3.75
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.03%
Amplitude
2.86%
Avg Price
2.450
Lot Size
2000
Float Cap
11.48B
Bid/Ask %
-12.64%
Historical High
5.980
Shs Float
4.63B
Volume Ratio
0.73
Historical Low
0.190
Dividend TTM
--
P/B
3.75
Dividend LFY
--
Turnover Ratio
0.03%
Amplitude
2.86%
Avg Price
2.450
Lot Size
2000
Price Forecast

No Data

News

Comment

Company Overview More
Xianjian Technology Co., Ltd. is a company mainly engaged in manufacturing and marketing minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The company operates through three business divisions. The congenital Heart Disease Division is engaged in the research, development, manufacture and trading of equipment related to the treatment of congenital and structural heart disease. The peripheral vascular disease business division is engaged in the research, development, manufacture and trading of equipment related to the treatment of peripheral vascular diseases. The surgical vascular repair business division is engaged in the research, development, manufacture and trading of equipment related to surgical vascular repair.
CEO: Yuehui Xie
Market: Hong Kong motherboard
Futu Hot List
HKUSCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top